Bank of America Corp Reports New 5.1% Stake in Mereo BioPharma Group plc

Bank of America Corp /DE/ has filed a Schedule 13G dated May 14, 2026, reporting a new 5.1% ownership stake in Mereo BioPharma Group plc. As of the event date of March 31, 2026, Bank of America beneficially owns 40,976,460 ordinary shares. This position represents a significant increase from a 0.0% previous ownership level, crossing the 5% regulatory threshold. The filing is made by Bank of America Corporation as a parent holding company on behalf of several subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International. The reported shares are held with shared voting and dispositive power. The filing indicates that the securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. The calculation of beneficial ownership is based on approximately 798 million outstanding shares reported by the issuer in March 2026.